--- title: "The concept of innovative drugs is strengthening, and the ChinaAMC CSI 500 ETF (512500) is steadily rising in the afternoon at a high level" type: "News" locale: "en" url: "https://longbridge.com/en/news/281312093.md" description: "The ChinaAMC CSI 500 ETF (512500) rose steadily in the afternoon, with the latest price at 4.313 yuan, an increase of 1.173%. The constituent stocks of the CSI 500 Index tracked by this ETF are active, with several small and mid-cap growth stocks rebounding. The liquidity is good, with a transaction volume reaching 204 million yuan. The innovative drug concept is gaining strength, with catalytic factors including over 60 billion USD in external licensing for innovative drugs in the first quarter, marking a harvest period for the industry. Changcheng Guorui Securities pointed out that the catalytic factors in the pharmaceutical and biotechnology sector continue to accumulate, with policy support and active overseas cooperation driving the valuation recovery of small and mid-cap stocks" datetime: "2026-04-01T06:13:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281312093.md) - [en](https://longbridge.com/en/news/281312093.md) - [zh-HK](https://longbridge.com/zh-HK/news/281312093.md) --- # The concept of innovative drugs is strengthening, and the ChinaAMC CSI 500 ETF (512500) is steadily rising in the afternoon at a high level As of 14:07, the ChinaAMC CSI 500 ETF (512500) experienced fluctuations in the morning and maintained a steady high position in the afternoon, with the latest price reported at 4.313 yuan, an increase of 1.173%. In terms of holdings, the constituent stocks of the CSI 500 index tracked by this ETF are actively rotating, with several small and mid-cap growth stocks rebounding strongly. Perfect World hit the daily limit, Junshi Biosciences rose nearly 10%, and China National Heavy Duty Truck Group and Yingfeng Environment saw significant gains. In terms of liquidity, the ETF's trading volume is steadily releasing, with a transaction amount reaching 204 million yuan and a turnover rate of 1.47%, maintaining stable trading activity in the market. Observing the intraday trend, the price fluctuated narrowly around the 4.313 yuan moving average in the afternoon. Strategically, it is recommended to pay attention to the sustainability of volume-price coordination, as the logic of small and mid-cap growth in the CSI 500 remains unchanged, and investors can use the fluctuation window to gradually accumulate shares. In terms of news, on April 1, the concept of innovative drugs in the A-share market continued to strengthen, with Guangsheng Tang and Ruizhi Pharmaceutical hitting the 20% daily limit, and many stocks rising sharply. Catalytic factors include: the external authorization amount for innovative drugs in the first quarter exceeded 60 billion USD; 10 innovative drugs have been approved this year (8 of which are domestically produced); pharmaceutical companies are turning losses into profits/high growth, and the industry is entering a harvest period; the sector's valuation is at historical lows, providing strong rebound momentum. Changcheng Guorui Securities stated that the catalytic factors for the pharmaceutical and biotechnology sector continue to accumulate, with drug and device innovation remaining the current core theme. On one hand, domestic policies continue to release positive signals, with the NMPA organizing a three-year "Clinical Innovation Results Transformation Spring Rain Action" nationwide to further strengthen support for the transformation and industrialization of innovative device results; on the other hand, overseas mergers, acquisitions, and authorized collaborations remain active, with the total amount of external authorization transactions for China's innovative drugs exceeding 60 billion USD in the first three months of 2026, approaching half of the total for the entire year of 2025. The participation and recognition of Chinese innovative drug assets in the global trading system continue to increase, further strengthening the pricing foundation of the "independent innovation + globalization realization" logic. The ChinaAMC CSI 500 ETF (512500) closely tracks the CSI 500 index, with low fees and small tracking errors, allowing for a one-click allocation to 500 high-quality mid-cap A-shares, efficiently diversifying risks and capturing the growth dividends of small and mid-cap stocks. Under the drive of economic structural upgrades and industrial innovation, the valuation repair space for small and mid-cap stocks is clear. The ChinaAMC CSI 500 ETF (512500) helps investors share in the economic growth dividends and is a core allocation tool for average returns in the A-share market. Daily Economic News ### Related Stocks - [512500.CN](https://longbridge.com/en/quote/512500.CN.md) - [510580.CN](https://longbridge.com/en/quote/510580.CN.md) - [510510.CN](https://longbridge.com/en/quote/510510.CN.md) - [510500.CN](https://longbridge.com/en/quote/510500.CN.md) - [000905.CN](https://longbridge.com/en/quote/000905.CN.md) - [159922.CN](https://longbridge.com/en/quote/159922.CN.md) ## Related News & Research - [NorthPalm Capital Launches as AI-Augmented Investment Company | SCYRF Stock News](https://longbridge.com/en/news/286914222.md) - [Israel-based Phase 3 ocular diseases biotech Tarsier Pharma sets terms for $45 million US IPO](https://longbridge.com/en/news/286793435.md) - [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md) - [08:49 ETPalo Alto Mind Body Pioneers Mental Health Equity with Low/No-Cost Ketamine Clinic and Announces Stanford-PAU Academic Partnership](https://longbridge.com/en/news/286915872.md) - [US retail group Catalyst Brands to expand India global centre, executive says](https://longbridge.com/en/news/286782924.md)